Navigation Links
Stemedica Forms Cardiology Division. Sergey Sikora, PhD Appointed As Division President
Date:2/15/2013

San Diego, CA (PRWEB) February 15, 2013

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research, development, and clinical applications announced today that it has formed a Cardiology Division to advance the Company’s national and international clinical trials in chronic heart failure, acute myocardial infarct (AMI) and other cardiac conditions.

Stemedica has made considerable progress in the translational applications of its ischemia tolerant adult allogeneic stem cells for cardiovascular diseases. The Company recently gained FDA approval for a multi-center Phase II clinical trial for intravenous treatment of AMI with its Stemedyne™-MSC product. Regulatory approval has also been granted to the National Medical Research Center in Astana, Kazakhstan for a Phase III trial with Stemedyne™-MSC. A Phase II clinical trial for chronic heart failure has begun at Hospital Angeles in Mexico. Additional cardiology trials with Stemedyne™-MSC are being planned in several countries around the world, including Switzerland and Indonesia.    

Dr. Sergey Sikora, the newly appointed Cardiology Division President, brings 12 years of experience in biomedical research, diagnostics and therapeutics in cardiology. Prior to Stemedica, he served as Senior Vice President and Scientific Advisory Board member of the FirstMark Cardiology Diagnostics Division of GenWay Inc. Dr. Sikora also worked with the Burnham Institute where he developed a novel bioinformatics/experimental biology streamlining methods for rapid experimental conformation of computational predictions. His work analyzing the genome of severe acute respiratory syndrome (SARS) resulted in a U.S. patent and a number of published research articles. Dr. Sikora obtained his PhD in molecular biology from UCLA and MBA from the Rady School of Management at the University of California, San Diego.

Nikolai Tankovich, MD, PhD, President and Chief Medical Officer of Stemedica commented, “This is a pivotal time to have an executive of Dr. Sikora’s caliber join our team. We have extensive interest worldwide in the application of our unique stem cells for heart and blood vessel diseases. Dr. Sikora will be coordinating the efforts of clinicians and researchers at multiple sites around the world.”

Dr. Sikora commented, “I am excited to contribute to Stemedica’s growth by utilizing my experience and contacts in the cardiology field to advance the science and translational efforts of stem cell treatments.”

Maynard Howe, PhD, Vice Chairman and CEO of Stemedica noted, “Our strategy as a company is to expand our clinical trials using our multiple cell lines to address specific medical indications. The company will continue to acquire additional strategic partners that share our vision of bringing our products to the millions of people around the world who suffer from serious cardiac conditions.”

About Stemedica Cell Technologies, Inc. http://www.stemedica.com
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc., contact Dave McGuigan at dmcguigan (at) stemedica.com.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10435703.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Stemedica and Scripps to Jointly Investigate Therapeutic Effect of Ischemia Tolerant Mesenchymal Stem Cells (itMSC) and Stem Cell Factors in Lung Injury and Sepsis
2. Marker distinguishes more-aggressive from less-aggressive forms of chronic leukemia
3. Metformin Outperforms Common Class of Diabetes Drugs in Study
4. Miami Children’s Hospital Performs First Nerve Repair Surgery Using Avance® Nerve Graft Technology
5. Study to evaluate zoning code reforms and physical activity
6. US performs worst on potentially preventable death rates compared to France, Germany, and the UK
7. Making People Sign Forms at the Top May Keep Them Honest
8. 4,000 analytics experts come to Phoenix for INFORMS Annual Meeting
9. Networks it takes a village approach improves dementia care and informs research, study shows
10. UCLA performs first breathing lung transplant in United States
11. FDA Clears Laser for all Critical Steps in Cataract Surgery: Center For Sight Performs the Most LENSAR Laser Procedures in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... newly redesigned website, federallabs.org . The site houses a wealth of federal ... federal technologies through the process called technology transfer (T2). As a network of ...
(Date:2/8/2016)... ... , ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens ... This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought ... remind them of the lives they’ve led and the people they’ve touched. , ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber Corporation ... to provide its range of unique and advantaged protective solutions to a ... will provide bilingual customer service and marketing support. A new distribution center in ...
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its affiliated companies ... Gary D. Radine, who recently retired as president and CEO of Delta Dental of ... CEO of the Year , helped lead the effort to raise funds for studies ...
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's document management software ... provides a cloud hosted environment for FileHold software that is pay per user ... party applications using the FileHold web services API. DocuSyst also advises clients on ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016 In a historic vote among its ... to construct a medical cannabis cultivation facility and dispensary on tribal land ... New York as a provider for patients in the state,s ... as a provider for patients in the state,s Medical Cannabis ... (34) to approve the project and pursue designation from the ...
(Date:2/8/2016)...   Intarcia Therapeutics, Inc. today announced the ... the newly created role of Vice President, Head of ... two decades of leadership experience at leading pharmaceutical, biotechnology, ... medical center. Most recently Dr. Yee served as VP, ... Head Medical Officer at AstraZeneca, where he led medical ...
(Date:2/8/2016)... PAOLI, Pa. , Feb. 8, 2016  As part ... Ltd has announced today the appointment of Lori Chmura ... more than 20 years in the industry, Chmura,s extensive experience ... in the advancement of Dune Medical Devices. ... Lori will be responsible for leading all sales, marketing and ...
Breaking Medicine Technology: